Breaking News

Anacor Appoints CEO

By Kristin Brooks | March 20, 2014

Berns brings more than 20 years of industry experience

Paul L. Berns has been appointed president and chief executive officer Anacor Pharmaceuticals, Inc. Mr. Berns previously served as Anacor’s chairman of the board of directors. Mr. Berns succeeds David P. Perry who has served as president and chief executive officer since 2002.
 
Mr. Berns has more than 20 years of industry experience having held executive roles in the pharma and biopharma industries. He most recently served as the president and chief executive officer of Allos Therapeutics.
 
“We appreciate David’s commitment to Anacor and the many contributions he has made over the past 12 years to help build Anacor into the company it is today,” said Paul Klingenstein, chair of the nominating and governance committee of the Anacor board. “We are delighted to have attracted a proven leader of Paul’s capabilities to assume the role of CEO for the next phase of Anacor’s growth. Having served as Chairman, Paul has a deep knowledge of Anacor’s management team, strategy, partners and development pipeline, thus enabling a smooth transition. Additionally, Paul’s significant commercial and product development experience, combined with his strategic and business development expertise, makes him ideally suited to lead Anacor as we seek to achieve our goals.”
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.